Secukinumab improves mild-to-moderate psoriasis: A randomized, placebo-controlled exploratory clinical trial

To the Editor: Many effective biologic treatments have been established for moderate-to-severe psoriasis, defined in most clinical trials as psoriasis with ≥10% body surface area and psoriasis area-and-severity index (PASI) ≥12. Although patients with mild-to-moderate psoriasis constitute 82% of the total psoriasis population, mild-to-moderate psoriasis patients are not permitted entry to clinical trials of newer biologic agents.1